论文部分内容阅读
目的:探讨三黄口服液对代谢综合征肥胖人群的临床疗效。方法:以20名健康志愿者为参照,将100名代谢综合征患者随机分为治疗组(60名)和安慰剂组(40名),分别予三黄口服液和安慰剂治疗12周,观察治疗前后患者心血管危险因素的变化。结果:与安慰剂组相比,治疗组(起效剂量为10 ml/人,黄连素浓度为0.16～0.22 mg/ml)除空腹血糖,甘油三酯在治疗前后无显著差异外,腰围、体质量指数、腰臀围比值、胰岛素抵抗指数,血清C反应蛋白水平、游离脂肪酸明显改善,差异有显著性(P<0.05);随着腰围的增大,男性的糖代谢异常、高血压病、血脂紊乱及代谢综合征的发生率均呈现增高趋势(P<0.01)。结论:三黄口服液可明显降低代谢综合征人群肥胖和胰岛素抵抗程度,并能改善炎症状态,减轻致心血管病的危险性。
Objective: To investigate the clinical effect of Sanhuang Oral Liquid on obese people with metabolic syndrome. Methods: A total of 100 patients with metabolic syndrome were randomly divided into treatment group (60 patients) and placebo group (40 patients) with 20 healthy volunteers. The patients were treated with Sanhuang oral liquid and placebo for 12 weeks, respectively. Changes of cardiovascular risk factors in patients before and after treatment. RESULTS: In addition to fasting plasma glucose, triglycerides had no significant difference in the treatment group (onset dose of 10 ml / person, berberine concentration of 0.16-0.22 mg / ml) and placebo group before and after treatment (P <0.05). With the increase of waist circumference, male patients with abnormal glucose metabolism, hypertension, hypertension, The incidence of dyslipidemia and metabolic syndrome showed an increasing trend (P <0.01). Conclusion: Sanhuang oral liquid can obviously reduce the degree of obesity and insulin resistance in the population with metabolic syndrome, and can improve the inflammatory state and reduce the risk of causing cardiovascular disease.